Epalrestat, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Epalrestat has been used as an aldose reductase inhibitor: in the dahomey larvae diet fed forDrosophilafor non-irradiated and X-ray irradiated human aldose reductaseto test its protective effect in mice with bleomycin-induced pulmonary fibrosis

Biochem/physiol Actions

Epalrestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Epalrestat is an approved drug in Japan and India, used for the treatment of diabetic neuropathy.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Other Notes

Light sensitve

Packaging

10, 50 mg in glass bottle